Citicoline Versus Alpha-GPC: Similar Goal, Different Molecules

Anyone shopping for a choline supplement quickly runs into the same two names. Citicoline and alpha-GPC are the premium cholinergic nootropics, both marketed for memory, focus, and brain health, and both aiming at broadly the same target: getting more choline to the brain to support acetylcholine and cell membranes. Because they share that goal, they are often treated as interchangeable, with the choice coming down to price or brand. They are not interchangeable. They are genuinely different molecules that deliver choline alongside a different second ingredient, and their evidence bases differ in ways that matter more than the marketing suggests. Sorting out what each one actually is, and what has actually been shown, is the point of this comparison.

What each molecule actually is

Citicoline is the common name for cytidine diphosphate-choline, or CDP-choline, which is identical to a natural intermediate the body already uses to build the membrane phospholipid phosphatidylcholine [1][2]. When you swallow it, it does not arrive at the brain intact. It is broken down in the gut and liver into two pieces, choline and cytidine, which circulate separately and are then reassembled inside brain cells [2]. A human pharmacokinetic study confirmed the practical result: oral citicoline raises plasma choline in a dose-dependent way, and it also raises plasma uridine, which is the form the cytidine portion takes in human blood [3]. So citicoline delivers choline plus a pyrimidine nucleoside that feeds into membrane synthesis, a point the companion article on membranes takes up in detail.

Alpha-GPC, or L-alpha-glycerylphosphorylcholine, also called choline alfoscerate, is a different compound: a molecule of choline attached to glycerophosphate. It is notably rich in choline by weight, is well absorbed, and crosses the blood-brain barrier to raise brain choline and support acetylcholine synthesis [10]. Its non-choline half is glycerophosphate rather than a nucleoside, which is the key molecular difference between the two. Reviews describe alpha-GPC as one of the more efficient forms for delivering choline to the brain and increasing acetylcholine release [11]. Both compounds, then, do reach the same destination of raising cholinergic capacity, but they carry different cargo alongside the choline, and that cargo is part of why their stories are not identical.

What the evidence shows for citicoline

Citicoline has the more direct evidence in healthy or near-healthy people. A randomized, double-blind, placebo-controlled trial in 100 healthy older adults with age-associated memory complaints found that 500 mg per day for twelve weeks improved memory, particularly episodic memory, relative to placebo [4]. Earlier placebo-controlled work reported improved attentional performance in healthy middle-aged women after 28 days [5] and improved attention and psychomotor speed in healthy adolescent males over the same period, with dose-related effects [6]. Broadening to clinical populations, a Cochrane systematic review of citicoline for cognitive and behavioural disturbances in elderly people with chronic cerebral disorders found some evidence of benefit for memory and behaviour, and for global clinical impression, though notably no clear benefit for attention [7]. Reviews of citicoline's pharmacology emphasize its role as a phospholipid and acetylcholine precursor and its good tolerability [13][14]. A fair reading is that citicoline has modest but genuine support, including a small number of trials in healthy adults, tempered by the fact that several of these studies were industry-funded.

What the evidence shows for alpha-GPC

Alpha-GPC's cognitive evidence is substantial but concentrated in a different population. Its most cited trial is a multicenter, double-blind, placebo-controlled study in patients with mild-to-moderate Alzheimer's dementia, where choline alfoscerate produced cognitive improvement over placebo across six months of treatment [8]. An analysis pooling thirteen clinical trials in more than four thousand patients with dementia or cerebrovascular disease likewise reported cognitive and functional benefits [9], and review articles describe animal and human findings supporting its role as a cognition-enhancing acetylcholine precursor [11]. The important qualification is that this evidence sits overwhelmingly in dementia and vascular populations rather than in healthy adults. Where alpha-GPC has been tested in healthy people, it has mostly been for physical and psychomotor performance: one controlled study found it improved countermovement jump power but showed no significant benefit for isometric strength or a psychomotor vigilance task [12]. The healthy-adult cognitive case for alpha-GPC is thinner than its reputation implies.

The rare head-to-head comparison

Direct comparisons between the two are scarce, which is itself worth knowing. A 2025 systematic review and meta-analysis pooled the three randomized trials that pitted choline alphoscerate against citicoline in patients with dementia disorders, covering 358 participants. On a standard geriatric clinical assessment scale, choline alphoscerate came out ahead of citicoline at the end of treatment, with advantages in cognitive function, affective symptoms, and everyday functioning, although the two did not differ on specific memory or word-fluency tests [16]. That is the strongest direct evidence available, and it modestly favors alpha-GPC. Two caveats keep it in perspective: the comparison exists only in dementia populations, so it says little about healthy users, and no head-to-head trial has compared the two for cognition in healthy adults at all. Anyone claiming a definitive winner for everyday use is going beyond the data.

Bioavailability, and the different second half

Both compounds succeed at their shared basic task of raising available choline, so the more interesting distinction is what else they bring. Alpha-GPC's high choline content and efficient delivery make it a strong pure choline donor [10]. Citicoline delivers somewhat less choline per dose but adds the cytidine-and-uridine component, which participates directly in the synthesis of membrane phospholipids and is the basis for citicoline's additional membrane-related rationale [2][3]. Neither difference makes one universally superior. They simply mean the two supplements are contributing to slightly different biochemistry beyond the choline they share, which is a better way to think about the choice than treating them as the same product under two labels.

Safety, and the alpha-GPC stroke question

Both are generally well tolerated, with citicoline in particular having a reassuring safety record across its clinical literature [14]. The one genuine safety question hangs over alpha-GPC. A very large population-based cohort study in South Korea, following more than twelve million adults, found that alpha-GPC users had a substantially higher ten-year risk of stroke, on the order of forty percent greater, in a dose-dependent pattern [15]. This finding deserves to be taken seriously and stated carefully. It is observational, not a controlled trial, which means it can show an association but not prove that alpha-GPC caused the strokes. Confounding by indication is a real possibility, since alpha-GPC is often prescribed to older people who already carry vascular and cognitive risk. The signal is not proof of harm, but it is not nothing either, and it is a reasonable input into a cautious decision, especially for anyone with cardiovascular risk factors. Citicoline carries no comparable signal in the current literature.

How to choose, given thin data

With the evidence laid out, a sensible way to choose emerges, and it is less exciting than the marketing but more honest. If your interest is everyday cognition as a healthy adult, citicoline has the more directly relevant human trials, because it is the one that has actually been tested in healthy people and shown small benefits to memory and attention [4][5][6]. If your interest is framed around age-related decline, both have been studied in that setting, with alpha-GPC carrying the larger dementia literature and the only head-to-head edge, though that edge comes with the caveats already noted [16]. And if cardiovascular risk is part of your picture, the unresolved stroke association gives a concrete reason to weight the decision toward citicoline, or at least to involve a clinician before choosing alpha-GPC [15]. None of this yields a universal ranking, because the trials that would settle it, direct comparisons in healthy adults, have not been run. The realistic goal is to match the choice to the evidence closest to your own situation rather than to a promise of superiority that neither molecule has earned.

Dosing and the honest bottom line

In practice, citicoline is typically used at 250 to 2000 mg per day, with 500 mg the common cognitive dose, while alpha-GPC is used at roughly 300 to 1200 mg per day, the higher end appearing in dementia trials. Beyond the numbers, the honest summary is this. Citicoline and alpha-GPC pursue the same goal through different molecules, each pairing choline with a distinct second component. Both have modest evidence, but citicoline has more of it in healthy adults, while alpha-GPC's stronger cognitive data lie in dementia populations and its healthy-adult case rests largely on physical-performance studies. The only direct head-to-head evidence is in dementia and slightly favors alpha-GPC, and the unresolved stroke association gives a reason for caution with it. None of this crowns a single best choice for everyone. It simply replaces the assumption that the two are the same with a clearer view of how they differ, so that a decision can rest on the evidence most relevant to you rather than on the confidence of a label.

This article is informational and not medical advice; anyone with cardiovascular or neurological risk factors should discuss these supplements with a clinician before use.

References

[1] Secades, J. J. (2016). Citicoline: pharmacological and clinical review, 2016 update. Revista de Neurología, 63(Suppl 3), S1–S73. https://pubmed.ncbi.nlm.nih.gov/28417449/

[2] Grieb, P. (2014). Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs, 28(3), 185–193. https://doi.org/10.1007/s40263-014-0144-8

[3] Wurtman, R. J., Regan, M., Ulus, I., & Yu, L. (2000). Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochemical Pharmacology, 60(7), 989–992. https://doi.org/10.1016/S0006-2952(00)00436-6

[4] Nakazaki, E., Mah, E., Sanoshy, K., Citrolo, D., & Watanabe, F. (2021). Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. The Journal of Nutrition, 151(8), 2153–2160. https://doi.org/10.1093/jn/nxab119

[5] McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., et al. (2012). Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences, 3(6), 769–773. https://doi.org/10.4236/fns.2012.36103

[6] McGlade, E., Agoston, A. M., DiMuzio, J., Kizaki, M., Nakazaki, E., Kamiya, T., & Yurgelun-Todd, D. (2019). The effect of citicoline supplementation on motor speed and attention in adolescent males. Journal of Attention Disorders, 23(2), 121–134. https://doi.org/10.1177/1087054715593633

[7] Fioravanti, M., & Yanagi, M. (2005). Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database of Systematic Reviews, (2), CD000269. https://doi.org/10.1002/14651858.CD000269.pub3

[8] De Jesus Moreno Moreno, M. (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. https://doi.org/10.1016/S0149-2918(03)90023-3

[9] Parnetti, L., Amenta, F., & Gallai, V. (2001). Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development, 122(16), 2041–2055. https://pubmed.ncbi.nlm.nih.gov/11589921/

[10] Kansakar, U., Trimarco, V., Mone, P., Varzideh, F., Lombardi, A., & Santulli, G. (2023). Choline supplements: an update. Frontiers in Endocrinology, 14, 1148166. https://doi.org/10.3389/fendo.2023.1148166

[11] Traini, E., Bramanti, V., & Amenta, F. (2013). Choline alphoscerate (alpha-glyceryl-phosphoryl-choline): an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Current Alzheimer Research, 10(10), 1070–1079. https://doi.org/10.2174/15672050113106660173

[12] Marcus, L., Soileau, J., Judge, L. W., & Bellar, D. (2017). Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. Journal of the International Society of Sports Nutrition, 14, 39. https://doi.org/10.1186/s12970-017-0196-5

[13] Gareri, P., Castagna, A., Cotroneo, A. M., Putignano, S., De Sarro, G., & Bruni, A. C. (2015). The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clinical Interventions in Aging, 10, 1421–1429. https://doi.org/10.2147/CIA.S87886

[14] Synoradzki, K., & Grieb, P. (2019). Citicoline: a superior form of choline? Nutrients, 11(7), 1569. https://doi.org/10.3390/nu11071569

[15] Lee, G., Choi, S., Chang, J., Choi, D., Son, J. S., Kim, K., et al. (2021). Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Network Open, 4(11), e2136008. https://doi.org/10.1001/jamanetworkopen.2021.36008

[16] Sagaro, G. G., & Amenta, F. (2025). Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Frontiers in Neurology, 16, 1649661. https://doi.org/10.3389/fneur.2025.1649661